Acute Vulvovaginal Candidiasis Treatment Market to Surpass US$ 397.8 Million by 2027

Global Acute Vulvovaginal Candidiasis Treatment Market, by Drug Type (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, and Others), by Route of Administration (Oral, Intravenous, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 308.0 million in 2020 and is estimated to exhibit a CAGR of 3.0% during the forecast period (2020-2027).

Increasing research and development for the treatment of vulvovaginal candidiasis is expected to drive growth of the global acute vulvovaginal candidiasis treatment market over the forecast period. For instance, on April 23, 2020, Scynexis, Inc. announced positive results for the Phase III trials, which were conducted for testing the safety and efficacy of the oral ibrexafungerp, a novel broad-spectrum antifungal drug, for the treatment of vulvovaginal candidiasis.

Market players are focused on submitting the new drug application (NDA) to the regulatory authorities for gaining approval for the drugs for the treatment of acute vulvovaginal candidiasis, which is expected to drive growth of the market over the forecast period. For instance, on October 14, 2020, Scynexis, Inc. submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (U.S. FDA) for oral ibrexafungerp, for the treatment of acute vulvovaginal candidiasis, after gaining positive results in Phase III clinical trials.

Global Acute Vulvovaginal Candidiasis Treatment Market - Impact of Coronavirus (COVID – 19) Pandemic

The COVID – 19 pandemic is expected to hamper growth of the global acute vulvovaginal candidiasis treatment market during the forecast period. The coronavirus cases are increasing at a very high rate across the globe. According to World Health Organization, on November 26, 2020, globally, 60,074,174 confirmed cases of COVID-19 and 1,416,292 deaths due to COVID-19 were reported.

Co-morbidities among the patients increases the chances of contracting coronavirus infection. For instance, according to Centers for Disease Control and Prevention, June 2020, diabetes patients are more susceptible to coronavirus infections and diabetes patients mostly suffer from recurrent vulvovaginal candidiasis. According to the same source, recovery rate of COVID-19 patients decreases with increasing co-morbidities, thus affecting the mortality rate among the patients.

Browse 39 Market Data Tables and 29 Figures spread through 152 Pages and in-depth TOC on, Global Acute Vulvovaginal Candidiasis Treatment, by Drug Type (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, and Others), by Route of Administration (Oral, Intravenous, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the acute vulvovaginal candidiasis treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/acute-vulvovaginal-candidiasis-treatment-market-4315

Increasing research and development for the treatment of fungal infections in burn patients is expected to support the research for developing new treatment for vulvovaginal candidiasis in future. This is expected to drive the market growth over the forecast period. For instance, according to the article published in the journal Wounds: 2018, a topical antifungal solution prepared from combining mafenide acetate 5% solution and nystatin showed drastic decrease in the infection caused by Candida species, Aspergillus species, and other fungi as well as the concomitant bacterial infection in burn patients. Currently, the study is in research phase.

Key Takeaways of the Acute Vulvovaginal Candidiasis Treatment:

• The global acute vulvovaginal candidiasis treatment is expected to exhibit a CAGR of 3.0% over the forecast period (2020-2027), owing to growth in potential markets, especially in Europe. North America accounted for major market share.
• Market players are indulged in extending their clinical trials for developing treatment for vulvovaginal candidiasis, which is expected to drive the market growth over the forecast period. For instance, on February 21, 2020, Mycovia Pharmaceuticals, Inc. extended their Phase III clinical trial for Oteseconazole (VT-1161), an oral antifungal drug, in order to gather more information regarding the drug safety and efficacy for the treatment of vulvovaginal candidiasis.
• Some of the major players operating in the global acute vulvovaginal candidiasis treatment market include Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.